CRO Sector In Good Health With More Consolidation Coming
The wave of merger and acquisitions that has washed through the contract research organization sector this year is set to continue as the pharmaceutical industry increasingly turns to outsourcing for its clinical needs.
You may also be interested in...
Takeda has chosen US-based PRA Health Sciences to lead its clinical development as part of the Japanese drug maker’s global R&D overhaul aimed at cutting costs and improving efficiency and innovation.
China’s WuXi AppTec is planning separate new stock listings for various parts of its business in both China and Hong Kong, potentially raising billions of dollars in the wake of an earlier go-private transaction.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.